Personalized medicine in hematologic malignancies: the ex-csepa model's role in Acinetobacter Baumannii bacteremia
DOI:
https://doi.org/10.1590/s2175-97902025e24443Keywords:
Hematologic malignancy, Acinetobacter baumannii, Bloodstream infection, 30-day survival, Predictive modelAbstract
The Ex-CSEPA model was developed to predict 30-day mortality for patients with hematologic malignancies after a standard 14-day antibiotic (ATB) treatment for Acinetobacter baumannii bacteremia. This study systematically evaluated the model’s performance in stratifying patients into high-risk and low-risk categories and compared the efficacy of extended ATB therapy with the standard 14-day course. The Ex-CSEPA model integrates several critical factors: extended course ATB (Ex), clinical improvement (C), starting ATB time (S), ECOG score (E), Pitt’s bacteremia score (P), and APACHE II score (A) to comprehensively assess mortality risk. The findings demonstrated that the Ex-CSEPA model effectively distinguished between high-risk and low-risk patients, with significant differences in mortality risks. High-risk patients had lower median survival compared to low-risk patients (p-value < 0.001), confirming the model’s accuracy. While extended ATB therapy did not improve overall survival rates, high-risk individuals benefited significantly. Extended ATB therapy reduced mortality by 32% and increased survival time by 66%, according to multivariable and Weibull proportional-hazards regression analyses. This study emphasizes the advantage of extended therapy for high-risk individuals and the usefulness of the Ex-CSEPA model in directing personalized treatment. In conclusion, the Ex-CSEPA model is a robust tool with substantial clinical implications, supporting personalized interventions with extended ATB therapy for high-risk patients and validating the standard 14-day course for low-risk individuals.
Downloads
References
Allegra A, Tonacci A, Musolino C, Pioggia G, Gangemi S. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. Front Immunol. 2021; 12:738915.
Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S, et al. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Case Rep Oncol. 2019;12(3):728-36.
Baker TM, Satlin MJ. The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies. Leuk Lymphoma. 2016;57(10):2245-58.
Chaiwarit R, Boonchuay M, Supparatpinyo K, Srisanthana T. Pandrug-Resistant Acinetobacter baumannii at Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents. 2005;22(108).
Chandra S, Kalashnikova T, Wright NAM, Dávila Saldaña BJ. Primary Immunodeficiencies and Hematologic Malignancies: A Diagnostic Approach. Front Immunol. 2022;13.
Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198-214.
Contejean A, Lemiale V, Resche-Rigon M, Mokart D, Pène F, Kouatchet A, et al. Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology: a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologique (Grrr-OH) study. Ann Intensive Care. 2016;6(1):102.
De Waele JJ, Martin-Loeches I. Optimal duration of antibiotic treatment in Gram-negative infections. Curr Opin Infect Dis. 2018;31(6):606-11.
Estcourt LJ, Stanworth SJ, Hopewell S, Doree C, Trivella M, Massey E. Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2016;4(4):Cd005339.
Garcia-Vidal C, Cardozo-Espinola C, Puerta-Alcalde P, Marco F, Tellez A, Agüero D, et al. Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS One. 2018;13(6):e0199531.
Im Y, Kang D, Ko R-E, Lee YJ, Lim SY, Park S, et al. Time-to-antibiotics and clinical outcomes in patients with sepsis and septic shock: a prospective nationwide multicenter cohort study. Crit Care. 2022;26(1):19.
Katip W, Uitrakul S, Oberdorfer P. Short-Course Versus Long-Course Colistin for Treatment of Carbapenem-Resistant A. baumannii in Cancer Patient. Antibiotics (Basel). 2021;10(5).
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-29.
Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6(1):8-14.
Nørgaard M, Larsson H, Pedersen G, Schønheyder HC, Sørensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006;12(3):217-23.
Park K-H, Jung YJ, Lee HJ, Kim HJ, Maeng CH, Baek SK, et al. Impact of multidrug resistance on outcomes in hematologic cancer patients with bacterial bloodstream infections. Sci Rep. 2024;14(1):15622.
Plackoska V, Shaban D, Nijnik A. Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression. Front Immunol. 2022;13.
Rhee J-Y, Kwon KT, Ki HK, Shin SY, Jung DS, Chung D-R, et al. Scoring System for Prediction of Mortality in Patients with Intensive Care Unit-Acquired Sepsis: A Comparison of the Pitt Bacteremia Score and the Acute Physiology And Chronic Health Evaluation II Scoring Systems. Shock. 2009;31(2):146-50.
Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(4):773-5.
Sousa A, Pérez-Rodríguez MT, Suárez M, Val N, Martínez-Lamas L, Nodar A, et al. Short- versus long-course therapy in gram-negative bacilli bloodstream infections. Eur J Clin Microbiol Infect Dis. 2019;38(5):851-7.
Tansarli GS, Andreatos N, Pliakos EE, Mylonakis E. A Systematic Review and Meta-analysis of Antibiotic Treatment Duration for Bacteremia Due to Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(5).
Tong-Minh K, Welten I, Endeman H, Hagenaars T, Ramakers C, Gommers D, et al. Predicting mortality in adult patients with sepsis in the emergency department by using combinations of biomarkers and clinical scoring systems: a systematic review. BMC Emerg Med. 2021;21(1):70.
Turkoglu M, Mirza E, Tunçcan Ö G, Erdem GU, Dizbay M, Yağcı M, et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011;26(5):460-7.
Vaquero-Herrero MP, Ragozzino S, Castaño-Romero F, Siller-Ruiz M, Sánchez González R, García-Sánchez JE, et al. The Pitt Bacteremia Score, Charlson Comorbidity Index and Chronic Disease Score are useful tools for the prediction of mortality in patients with Candida bloodstream infection. Mycoses. 2017;60(10):676-85.
Weinstein MP, Lewis JS, 2nd. The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes. J Clin Microbiol. 2020;58(3).
Downloads
Published
Data Availability Statement
Not informed.
Issue
Section
License
Copyright (c) 2025 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
